X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs CIPLA - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA CIPLA SANOFI INDIA/
CIPLA
 
P/E (TTM) x 33.6 44.6 75.3% View Chart
P/BV x 6.4 3.8 167.3% View Chart
Dividend Yield % 1.4 0.3 420.1%  

Financials

 SANOFI INDIA   CIPLA
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
CIPLA
Mar-17
SANOFI INDIA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs4,560622 733.2%   
Low Rs4,400458 960.1%   
Sales per share (Unadj.) Rs1,028.5181.9 565.6%  
Earnings per share (Unadj.) Rs129.012.9 1,002.0%  
Cash flow per share (Unadj.) Rs186.029.3 634.4%  
Dividends per share (Unadj.) Rs68.002.00 3,400.0%  
Dividend yield (eoy) %1.50.4 409.9%  
Book value per share (Unadj.) Rs753.6155.7 484.1%  
Shares outstanding (eoy) m23.03804.51 2.9%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.43.0 146.7%   
Avg P/E ratio x34.742.0 82.8%  
P/CF ratio (eoy) x24.118.4 130.7%  
Price / Book Value ratio x5.93.5 171.4%  
Dividend payout %52.715.5 339.3%   
Avg Mkt Cap Rs m103,174434,516 23.7%   
No. of employees `0003.623.0 15.7%   
Total wages/salary Rs m3,59226,338 13.6%   
Avg. sales/employee Rs Th6,537.76,349.1 103.0%   
Avg. wages/employee Rs Th991.41,143.0 86.7%   
Avg. net profit/employee Rs Th819.8449.3 182.4%   
INCOME DATA
Net Sales Rs m23,686146,302 16.2%  
Other income Rs m7082,287 31.0%   
Total revenues Rs m24,394148,589 16.4%   
Gross profit Rs m5,28124,758 21.3%  
Depreciation Rs m1,31313,229 9.9%   
Interest Rs m151,594 0.9%   
Profit before tax Rs m4,66112,222 38.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6911,798 94.1%   
Profit after tax Rs m2,97010,354 28.7%  
Gross profit margin %22.316.9 131.8%  
Effective tax rate %36.314.7 246.7%   
Net profit margin %12.57.1 177.2%  
BALANCE SHEET DATA
Current assets Rs m15,67387,370 17.9%   
Current liabilities Rs m6,67833,081 20.2%   
Net working cap to sales %38.037.1 102.3%  
Current ratio x2.32.6 88.9%  
Inventory Days Days7687 87.4%  
Debtors Days Days2262 35.8%  
Net fixed assets Rs m8,098111,567 7.3%   
Share capital Rs m2301,609 14.3%   
"Free" reserves Rs m17,088123,645 13.8%   
Net worth Rs m17,356125,254 13.9%   
Long term debt Rs m036,454 0.0%   
Total assets Rs m25,400209,532 12.1%  
Interest coverage x311.78.7 3,596.3%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.90.7 133.6%   
Return on assets %11.85.7 206.1%  
Return on equity %17.18.3 207.0%  
Return on capital %26.98.5 317.0%  
Exports to sales %24.534.2 71.6%   
Imports to sales %28.08.3 335.4%   
Exports (fob) Rs m5,80150,050 11.6%   
Imports (cif) Rs m6,62712,203 54.3%   
Fx inflow Rs m7,14551,066 14.0%   
Fx outflow Rs m6,84617,678 38.7%   
Net fx Rs m29933,388 0.9%   
CASH FLOW
From Operations Rs m3,22623,824 13.5%  
From Investments Rs m-1,555-13,127 11.8%  
From Financial Activity Rs m-1,818-13,239 13.7%  
Net Cashflow Rs m-147-2,478 5.9%  

Share Holding

Indian Promoters % 0.0 16.0 -  
Foreign collaborators % 60.4 20.8 290.4%  
Indian inst/Mut Fund % 14.4 12.2 118.0%  
FIIs % 14.6 23.7 61.6%  
ADR/GDR % 0.0 1.1 -  
Free float % 10.5 26.2 40.1%  
Shareholders   15,184 161,166 9.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   ORCHID PHARMA LTD  STERLING BIOTECH  ASTRAZENECA PHARMA  SUVEN LIFE  IPCA LABS  

Compare SANOFI INDIA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Feb 23, 2018 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - DR. REDDYS LAB COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS